Free Access
Med Sci (Paris)
Volume 24, Number 10, Octobre 2008
Page(s) 821 - 827
Section M/S revues
Published online 15 October 2008
  1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3 : 917–21. [Google Scholar]
  2. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999; 23 : 387–8. [Google Scholar]
  3. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10 : 1319–28. [Google Scholar]
  4. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8 : 61–70. [Google Scholar]
  5. Xia F, Altieri DC. Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 2006; 66 : 3392–5. [Google Scholar]
  6. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19 : 617–23. [Google Scholar]
  7. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001; 169 : 155–64. [Google Scholar]
  8. Knauer SK, Bier C, Schlag P, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007; 6 : 1502–9. [Google Scholar]
  9. O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97 : 13103–7. [Google Scholar]
  10. Zhao J, Tenev T, Martins LM, et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000; 113 : 4363–71. [Google Scholar]
  11. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100 : 13791–6. [Google Scholar]
  12. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8 : 798–812. [Google Scholar]
  13. Delacour-Larose M, Thi MN, Dimitrov S, Molla A. Role of survivin phosphorylation by aurora B in mitosis. Cell Cycle 2007; 6 : 1878–85. [Google Scholar]
  14. Vong QP, Cao K, Li HY, et al. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 2005; 310 : 1499–504. [Google Scholar]
  15. Jeyaprakash AA, Klein UR, Lindner D, et al. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007; 131 : 271–85. [Google Scholar]
  16. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000; 19 : 3225–34. [Google Scholar]
  17. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1 : 461–6. [Google Scholar]
  18. Vogel, C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007; 67 : 339–45. [Google Scholar]
  19. Ghosh JC, Dohi T, Raskett CM, et al. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 2006; 66 : 11576–9. [Google Scholar]
  20. Blanchard JM. Des oncogènes aux régulateurs de la mitose: un changement de perspective dans notre vision des processus cancéreux. Med Sci (Paris) 2003; 19 : 187–99. [Google Scholar]
  21. Verdecia MA, Huang H, Dutil E, et al. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7 : 602–8. [Google Scholar]
  22. Liu, T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23 : 39–48. [Google Scholar]
  23. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23 : 7494–506. [Google Scholar]
  24. Laudet B, Prudent R, Filhol O, Cochet C. Des agents thérapeutiques ciblant des interactions protéine-protéine : mythe ou réalité ? Med Sci (Paris) 2007; 23 : 273–8. [Google Scholar]
  25. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279 : 34087–90. [Google Scholar]
  26. Song, Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278 : 23130–40. [Google Scholar]
  27. Arora V, Cheung HH, Plenchette S, et al. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007; 282 : 26202–9. [Google Scholar]
  28. Didelot C, Garrido C. HSP90 mitochondriale : la cible à inactiver dans la thérapie anti-cancéreuse ? Med Sci (Paris) 2008; 24 : 363–4. [Google Scholar]
  29. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003; 22 : 2729–40. [Google Scholar]
  30. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 281 : 33450–6. [Google Scholar]
  31. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114 : 1117–27. [Google Scholar]
  32. Ceballos-Cancino G, Espinosa M, Maldonado V, et al. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007; 26 : 7569–75. [Google Scholar]
  33. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007; 27 : 17–28. [Google Scholar]
  34. Thomas J, Liu T, Cotter MA, et al. Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res 2007; 67 : 5172–8. [Google Scholar]
  35. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5 : 1087–98. [Google Scholar]
  36. Romagnoli M, Trichet V, David C, et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007; 21 : 1070–8. [Google Scholar]
  37. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28 : 1133–9. [Google Scholar]
  38. Kenney DM, Geschwindt RD, Kary MR, et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 2007; 28 : 57–62. [Google Scholar]
  39. Yie SM, Luo B, Ye NY, et al. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis 2006; 23 : 279–89. [Google Scholar]
  40. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158 : 1757–65. [Google Scholar]
  41. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006; 5 : 478–82. [Google Scholar]
  42. Tolcher. A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors. Atlanta, USA : American Society of Clinical Oncology, 2006. [Google Scholar]
  43. Arrigo AP. Chaperons moléculaires et repliement des protéines : l’exemple de certaines protéines de choc thermique. Med Sci (Paris) 2005; 21 : 619–25. [Google Scholar]
  44. Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005; 7 : 457–68. [Google Scholar]
  45. Li B, Liu X, Fan J, et al. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J Gene Med 2006; 8 : 1232–42. [Google Scholar]
  46. Grube M, Moritz S, Obermann EC, et al. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 2007; 13 : 1053–60. [Google Scholar]
  47. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005; 65 : 553–61. [Google Scholar]
  48. Hadrup SR, Gehl J, Sørensen RB, et al. Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther 2006; 5 : 480–2. [Google Scholar]
  49. Sausville EA, Tomaszewski JE, Ivy. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3 : 377–83. [Google Scholar]
  50. Meli M, Pennati M, Curto M, et al. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem 2006; 49 : 7721–30. [Google Scholar]
  51. Chen JS, Liu JC, Shen L, et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11 : 740–7. [Google Scholar]
  52. Otto K, Andersen MH, Eggert A, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23 : 884–9. [Google Scholar]
  53. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2 : 19. [Google Scholar]
  54. Delacour-Larose M, Nhung Hoang TM, Molla A. Survivine, la petite reine du complexe passager : check-up pour son dixième anniversaire. Med Sci (Paris) 2008; 24 : 828–32. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.